Ovulation inhibition by the monophasic oral contraceptive containing 75 μg of gestodene
and 30 wg of ethinyl estradiol was evaluated in 25 healthy volunteers for five cycles: a …

Twenty-five healthy women volunteers were selected to evaluate ovulation inhibition by a
monophasic oral contraceptive preparation containing 75 micrograms gestodene and 30 …

The minimal effective dose of gestodene for inhibition of ovulation was studied in 30 female
volunteers. Daily doses of 10 μg to 50 μg gestodene were given orally for 21 days. A control …

An open label, non-comparative study was carried out in 22 women over a total of five
cycles. After an untreated cycle, oral administration of 20 μg ethinyl estradiol (EE) with 50 μg …

Objective: To compare ovulation inhibition and ovarian activity with 21-day and 24-day
regimens of a low-dose combined oral contraceptive (COC) containing 60 μg of gestodene …

Efforts to minimize oral contraceptive side effects have focused on the use of new dosage
schemes and the synthesis of new steroids that can be used in safer, low-dose formulations …

Fifty-three women were randomly allocated to one of two combined low-dose monophasic
oral contraceptives (20 μg ethinyl estradiol with 75 μg gestodene or 20 μg ethinyl estradiol …

Oral contraceptives inhibit ovarian follicular growth by suppressing the release of
gonadotropins from the pituitary. We studied basal and gonadotropin-releasing hormone …

OBJECTIVE: Our purpose was to test the hypothesis that omitting the first three pills of the
contraceptive cycle leads to ovulation. STUDY DESIGN: Ninety-nine women, randomly …

The contraceptive efficacy, tolerance, and safety of a new monophasic oral contraceptive
that combines 75 mcg gestodene (delta-15-levonorgestrel) and 30 mcg ethinyl estradiol …